Journal of Applied Physiology (2011) 2
Another phase II randomized pilot study that aimed to evaluate the same melanotan I implant and narrow-band ultraviolet B (NB-UVB) light was also published in 2011
In T2DM, they are typically recommended as second-line or add-on therapymost often after metformin failureand more recently as first-line agents in people with established cardiovascular or renal disease [15, 16]
The glucose-dependent nature of their action reduces the risk of hypoglycemia compared to traditional diabetes medications
Dosing is personalised based on treatment goals, HbA1c levels, body weight, renal function, concurrent medications, and tolerability
Across all trials, the side effect profile of AOD 9604 was described as indistinguishable from placebo